Literature DB >> 25327618

Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population.

Jeremy Y C Teoh1, Samson Y S Chan1, Peter K F Chiu1, Darren M C Poon2, Ho-Yuen Cheung3, Simon S M Hou1, Chi-Fai Ng1.   

Abstract

OBJECTIVE: To investigate the risk of acute myocardial infarction (AMI) after androgen-deprivation therapy (ADT) for prostate cancer in a Chinese population. PATIENTS AND METHODS: All Chinese patients with prostate cancer who were treated primarily with radical prostatectomy or radiotherapy, with or without further ADT at our hospital from the year 2000 to 2009 were retrospectively reviewed. We compared the risk of AMI in the patients who were given further ADT (ADT group) with those who were not given any ADT (non-ADT group). Potential risk factors of AMI including age, diabetes mellitus, hypertension, hyperlipidaemia, history of stroke, ischaemic heart disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and duration of ADT were reviewed. The risk of AMI after ADT was first analysed using the Kaplan-Meier method, followed by Cox regression analyses including the potential risk factors mentioned.
RESULTS: In all, 452 patients were included, with 200 patients in the non-ADT group and 252 patients in the ADT group. The mean (sd) age was 68.2 (5.9) years in the non-ADT group and 69.5 (6.5) years in the ADT group, and the difference was statistically significant (P = 0.031). There were no significant differences in their pre-existing medical conditions or ECOG PS. The ADT group was associated with an increased risk of AMI when compared with the non-ADT group (P = 0.004) upon Kaplan-Meier analysis. Upon multivariate Cox regression analysis, hyperlipidaemia, poor ECOG PS and the use of ADT were the only three significant factors that were associated with increased risk of developing new AMI.
CONCLUSIONS: There was increased risk of AMI after ADT for prostate cancer in a Chinese population. Hyperlipidaemia and poor ECOG PS were also significant risk factors for developing AMI. The risk of AMI should be considered when deciding on ADT, especially in patients with history of hyperlipidaemia and relatively poor ECOG PS.
© 2014 The Authors. BJU International © 2014 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Chinese population; androgen-deprivation therapy; myocardial infarction; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 25327618     DOI: 10.1111/bju.12967

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

Review 1.  Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.

Authors:  Jeremy Yuen Chun Teoh; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2016-06-02       Impact factor: 2.370

2.  Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.

Authors:  Thiago Gagliano-Jucá; Karol M Pencina; Tomas Ganz; Thomas G Travison; Philip W Kantoff; Paul L Nguyen; Mary-Ellen Taplin; Adam S Kibel; Zhuoying Li; Grace Huang; Robert R Edwards; Elizabeta Nemeth; Shehzad Basaria
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-16       Impact factor: 4.310

3.  Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.

Authors:  Chris Wong; Peggy Chu; Jeremy Teoh; Peter Chiu; C H Yee; Lysander Chau; Marco Chan; Helen Wan; Steven Leung; C F Ng
Journal:  Int Urol Nephrol       Date:  2022-02-25       Impact factor: 2.370

4.  A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.

Authors:  Joseph K M Li; Lynn L Wang; Christine Y P Wong; Peter K F Chiu; Jeremy Y C Teoh; Hilda S W Kwok; Steven C H Leung; Sunny H Wong; Stephen K W Tsui; Chi-Fai Ng
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-13       Impact factor: 5.455

5.  Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.

Authors:  Myungsun Shim; Woo Jin Bang; Cheol Young Oh; Yong Seong Lee; Seong Soo Jeon; Hanjong Ahn; Young-Su Ju; Jin Seon Cho
Journal:  PLoS One       Date:  2020-12-30       Impact factor: 3.240

6.  Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study.

Authors:  Hsin-Le Lin; Chia-Yi Lee; Jing-Yang Huang; Po-Chen Tseng; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

7.  Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study.

Authors:  Youquan Li; Whee Sze Ong; Ma Than Than Shwe; Nelson Ling Fung Yit; Sheriff Zhan Hong Quek; Eric Pei Ping Pang; Wen Shen Looi; Wen Long Nei; Michael Lian Chek Wang; Melvin Lee Kiang Chua; Terence Wee Kiat Tan; Eu Tiong Chua; Choon Ta Ng; Jeffrey Kit Loong Tuan
Journal:  Cardiooncology       Date:  2022-03-14

8.  Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.

Authors:  Hsiang Ying Lee; Hsiao-Ling Chen; Jeremy Yuen-Chun Teoh; Tun-Chieh Chen; Shao-Yuan Hao; Hsin-Yi Tsai; Wei-Hsuan Huang; Yung-Shun Juan; Hao-Min Cheng; Hsiu-Mei Chang
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-28       Impact factor: 5.554

9.  Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.

Authors:  Kuang-Ming Liao; Yaw-Bin Huang; Chung-Yu Chen; Chen-Chun Kuo
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

10.  Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study.

Authors:  Chi-Fai Ng; Peter K F Chiu; Chi-Hang Yee; Becky S Y Lau; Steven C H Leung; Jeremy Y C Teoh
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.